Dan co-founder / CEO of Valocor Therapeutics. Led company until its acquisition by Dermira in 2011. Prior to Valocor, Dan was VP Commercial at QLT and served as President of its QLT Specialty Medicine division. Dan previously held senior positions in several pharma/biotech companies including Schering-Plough and Johnson & Johnson, where he was responsible for the US launch of Remicade, achieving over $8B in annual sales worldwide.

Dr. Julien is a world leader in ALS and neurodegenerative disease. He has published over 160 peer-reviewed papers, many in top ranked journals such as: Cell, Neuron, Science, Nature, among others. He is a member of the Robert Packard Center for ALS at Johns Hopkins University, the Gairdner Medical Review Panel, the ALS Society of Canada and is a recipient of the prestigious Sheila Essey Award for research from the American Academy of Neurology.

Dr. Levy was co-founder of QLT and had served as its CEO and CSO. She has been the recipient of many awards for her achievements in business and science including: the Order of Canada, the Female Entrepreneur of the Year, the Friesen-Rygiel prize for medical research and the Prix Galien Canada research award. She has also served as a Director of numerous biotechnology companies including AnoMED, Aspreva, Cynapsus, Twinstrand, Valocor and Vida.